Dyne Therapeutics, Inc.
DYN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818794
In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Dyne Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 10 filings
- 6 insiders, $90.2M in total
- Insiders trading
- 6
- Net value
- −$90.2M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Dyne Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer | 152,897 | Sep 8, 2026 | 7 |
| Kerr Douglas | Chief Medical Officer | 162,564 | Sep 8, 2026 | 7 |
| Cox John | CEO & President | 357,507 | Sep 8, 2026 | 7 |
| Rhodes Jason P | Director | 428,946Indirect | Aug 17, 2026 | 9 |
| Lucera Erick | Chief Financial Officer | 119,766 | Aug 17, 2026 | 5 |
| Kersten Dirk | Director | 3,586,796Indirect | Jul 29, 2026 | 9 |
| Greene Barry E | Director | – | Jun 23, 2026 | 1 |
| Hurwitz Edward | Director | – | Jun 9, 2026 | 1 |
| Posner Brian S | Director | 24,500 | Jun 9, 2026 | 8 |
| Lubner David Charles | Director | 0 | Jun 9, 2026 | 2 |
| Stehman-Breen Catherine | Director | – | Jun 9, 2026 | 1 |
| Incerti Carlo | Director | 0 | Jun 9, 2026 | 1 |
| Karnani Vikram | Director | – | Dec 23, 2025 | 1 |
| Scalzo Richard William | SVP, Head of Finance & Admin. | 122,330 | Mar 13, 2025 | 0 |
| Beskrovnaya Oxana | Chief Scientific Officer | 195,840 | Mar 13, 2025 | 0 |
| High Susanna Gatti | Chief Operating Officer | 131,636 | Sep 19, 2024 | 0 |
| McNeill Jonathan | Chief Business Officer | 132,106 | Aug 20, 2024 | 0 |
| Farwell Wildon | Chief Medical Officer | 143,222 | Aug 20, 2024 | 0 |
| Brumm Joshua T | CEO & President | 537,998 | Mar 12, 2024 | 0 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Opportunity Fund II, L.P. | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Associates Opportunity II, LLC | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Associates Opportunity II, LP | 10% Owner | 847,388Indirect | Mar 5, 2024 | 0 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 864,487Indirect | Feb 28, 2024 | 0 |
| Atlas Venture Associates XI, LLC | 10% Owner | 864,487Indirect | Feb 28, 2024 | 0 |
| Atlas Venture Associates XI, L.P. | 10% Owner | 864,487Indirect | Feb 28, 2024 | 0 |
| Klein Lawrence Otto | Director | – | Jul 6, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Beskrovnaya OxanaChief Scientific Officer | SSale | −693 | $8.73 | −$6.05K | −1.3%53.7K after | |
| Mar 3, 2022 (view filing) | Mar 2 | 1 day | Farwell WildonChief Medical Officer | SSale | −5.62K | $8.56 | −$48.1K | −7.8%66.7K after | |
| Sep 24, 2021 (view filing) | Sep 23 | 1 day | High Susanna GattiChief Operating Officer | SSale | −2.45K | $17.22 | −$42.2K | −6.8%33.5K after | |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | Scalzo Richard WilliamSee Remarks | SSale | −859 | $15.90 | −$13.7K | −7.5%10.6K after | 2 lots |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | McNeill JonathanSee Remarks | SSale | −1.27K | $15.90 | −$20.3K | −3.5%35.6K after | 2 lots |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | Brumm Joshua TSee Remarks | SSale | −8.01K | $15.90 | −$127.3K | −7.5%99.0K after | 2 lots |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | Beskrovnaya OxanaChief Scientific Officer | SSale | −1.44K | $15.90 | −$23.0K | −7.5%17.8K after | 2 lots |